Sponsored diagnostic testing programs for ALG12-Congenital Disorder of Glycosylation (CDG-Ig)
ALG12-congenital disorder of glycosylation (ALG12-CDG, CDG-Ig) is a rare inherited condition caused by defects in the glycosylation of proteins, affecting multiple organ systems. Symptoms may include developmental delay, hypotonia, seizures, immune dysfunction, and growth issues. Genetic testing is essential for confirming the diagnosis and guiding management and counseling.
1 program found for ALG12-Congenital Disorder of Glycosylation (CDG-Ig)
This program provides access to genetic testing for pediatric patients under 18 who present with an unprovoked seizure. The panel evaluates key epilepsy-associated genes to support diagnostic confirmation, inform prognosis, and guide clinical management. Testing is available to eligible patients when ordered by a licensed healthcare provider.
